Relevance of serologic studies in inflammatory bowel disease

被引：41

作者：

Vernier G. ^{[1
]}

Sendid B. ^{[1
]}

Poulain D. ^{[1
]}

Colombel J.-F. ^{[1
]}

机构：

[1] Service des Maladies, Appareil Digestif et de la Nutrition, CHRU Claude Huriez

来源：

Current Gastroenterology Reports | 2004年 / 6卷 / 6期

关键词：

Inflammatory Bowel Disease; Ulcerative Colitis; Celiac Disease; Indeterminate Colitis; Small Bowel Disease;

D O I：

10.1007/s11894-004-0070-x

中图分类号：

学科分类号：

摘要：

The serologic panel for inflammatory bowel disease (IBD) is rapidly expanding. Antineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae mannan antibodies (ASCA) have remained the most widely studied markers, but immune reactivity against a new group of bacterial antigens such as 12, OmpC (outer membrane porin C), and flagellin, has been described in Crohn's disease. Several clinical avenues have been explored, such as the usefulness of serologic markers as screening tools for IBD and in accelerating a diagnosis in patients with indeterminate colitis. Another area of interest is disease stratification. Emerging data suggest there is a diversity of qualitative and quantitative responses to environmental antigens that differs among groups of IBD patients and may be associated with different clinical behaviors. As a result, it may be possible to tailor therapy on the basis of serologic responses. Prospective studies are needed before translating this concept into clinical practice. Clustering of IBD patients into more homogeneous subgroups based on antibody responses may help to unravel the pathophysiology of subsets of IBD. Copyright © 2004 by Current Science Inc.

引用

页码：482 / 487

页数：5

共 36 条

[1]

Reumaux D., Sendid B., Poulain D., Et al., Serological markers in inflammatory bowel diseases, Best Pract. Res. Clin. Gastroenterol., 17, pp. 19-35, (2003)

[2]

Colombel J.F., Reumaux D., Sendid B., Et al., Serodiagnostics in IBD, In the Inflammatory Bowel Disease Yearbook 2003, pp. 63-78, (2003)

[3]

Klebl F.H., Bataille F., Hofstadter F., Et al., Optimising the diagnostic value of Anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease, Int. J. Colorectal Dis., 19, pp. 319-324, (2004)

[4]

Sendid B., Colombel J.F., Jacquinot P.M., Et al., Specific antibody response to oligomannosidic epitopes in Crohn's disease, Clin. Diagn. Lab. Immunol., 3, pp. 219-226, (1996)

[5]

Vandewalle P., Standaert A., Seddik M., Et al., A new ASCA test based on synthetic oligomannosides epitopes complements ASCA detection in both Crohn's disease and indeterminate colitis, Gastroenterology, 126, (2004)

[6]

Joossens S., Vermeire S., Van Steen C., Et al., Pancreatic autoantibodies in inflammatory bowel disease, Inflamm. Bowel Dis., (2004)

[7]

Landers C.J., Cohavy O., Misra R., Et al., Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens, Gastroenterology, 123, pp. 689-699, (2002)

[8]

Linskens R.K., Mallant-Hent R.C., Groothuismink Z.M.A., Et al., Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods, Eur. J. Gastroenterol. Hepatol., 14, pp. 1013-1017, (2002)

[9]

Lodes M.J., Cong Y., Elson C.O., Et al., Bacterial flagellin is a dominant antigen in Crohn disease, J. Clin. Invest., 113, pp. 1296-1306, (2004)

[10]

Targan S.C.J.L., Lodes M., Et al., Antibodies to a novel flagellin (CBir1) define a unique serologic response in Crohn's disease, Gastroenterology, 126, (2004)

← 1 2 3 4 →